Evidence map›Paper›PMID 27295974›Full record

ReviewAmerican journal of Alzheimer's disease and other dementias2016

Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease.

Delaram Safarpour, Allison W Willis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of Alzheimer's disease and other dementias, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Update on Major Neurocognitive Disorders.Focus (American Psychiatric Publishing) · 2021
    Article
  7. PINK1: Multiple mechanisms of neuroprotection.International review of movement disorders · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Parkinson's Disease: Cognitive Impairment.Focus (American Psychiatric Publishing) · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Delaram SafarpourDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Parkinson's Disease Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, PA, USA.
Allison W WillisDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA allison.willis@uphs.upenn.edu.

Funding

Parkinson Disease Disparities and OutcomesK23NS081087 · NINDS · WASHINGTON UNIVERSITY · PI WILLIS, ALLISON · 2012 to 2015
$669k
NINDS NIH HHS K23 NS081087
6 · The paper itself

Abstract

The prevalence of neurodegenerative diseases such as Parkinson disease (PD) will increase substantially, due to the aging of the population and improved treatments leading to better disease-related outcomes. Dementia is the most common nonmotor symptom in PD, and most patients with PD will have cognitive dysfunction and cognitive decline in the course of their disease. The development of cognitive dysfunction in PD greatly limits the ability to participate in activities of daily living and can be a tipping point for nursing home placement or major caregiver stress. Understanding the different causes of dementia and how to reduce the incidence and impact of secondary cognitive dysfunction in PD are necessary skills for primary care physicians and neurologists. In this review, we discuss the clinical epidemiology of dementia in PD with an emphasis on preventable cognitive dysfunction, present tools for outpatient evaluation of cognitive dysfunction, and describe current pharmacological treatments for dementia in PD.

Indexed as

Cognitive DysfunctionDementiaHumansParkinson Diseasedementiaepidemiologymild cognitive impairmentParkinson diseaseParkinson disease with dementia

Identifiers

PMID27295974
PMCPMC10852884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.